Major histocompatibility complex class I C (HLA-C); major histocompatibility complex class II DQ α1 (HLA-DQA1); HLA-DQB1; major histocompatibility complex class II DR β1 (HLA-DRB1) BriefCommunication Pages: 1558 - 1558
ATG3 autophagy-related 3 homolog (ATG3); viral FLICE-like inhibitory protein (FLIP) BriefCommunication Pages: 1561 - 1561
Mammalian target of rapamycin (mTOR; FRAP; RAFT1); mTOR complex 1 (mTORC1); mTORC2 BriefCommunication Pages: 1563 - 1563
T helper 17 (Th17) cells; IL-17; chemokine CC motif ligand 20 (CCL20; MIP3A); monocyte chemoattractant protein-1 (MCP-1; CCL2) BriefCommunication Pages: 1564 - 1564
Epidermal growth factor receptor 1 (HER1; ERBB1); HER2 (ERBB2; neu) BriefCommunication Pages: 1567 - 1567
Transient receptor potential cation channel, subfamily C, member 3 (TRPC3) BriefCommunication Pages: 1573 - 1573
9-Hydroxyoctadecadienoic acid (9-HODE); 9-oxo-octadecadienoic acid (9-oxoODE); 13-hydroxyoctadecadienoic acid (13-HODE); 13-oxo-octadecadienoic acid (13-oxoODE); transient receptor potential vanilloid 1 (TRPV1; VR1) BriefCommunication Pages: 1577 - 1577
Prostate-specific antigen (PSA) assay for early detection of prostate cancer recurrence BriefCommunication Pages: 1580 - 1580
Marker interaction–based algorithms to improve genotype-based disease risk assessment BriefCommunication Pages: 1581 - 1581
Extending the half-life of mAb therapeutics by blocking proteolytic cleavage BriefCommunication Pages: 1583 - 1583
Chemical platform for generation of human induced pluripotent stem (iPS) cells BriefCommunication Pages: 1584 - 1584
Infectious agent–neutralizing, bifunctional small molecules that recruit naturally occurring dinitrophenol (DNP) antibodies BriefCommunication Pages: 1585 - 1585
Molecular markers of truly pluripotent human induced pluripotent stem (iPS) cells BriefCommunication Pages: 1586 - 1586
Myeloid leukemia cell differentiation protein (Mcl-1) dependency as a marker for chemotherapy sensitivity BriefCommunication Pages: 1587 - 1587
